Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

79
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
79
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

613
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
613
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

89
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
89
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report.

The journal of allergy and clinical immunology. Global·2026
Same author

Aspirin Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.

Biomedicines·2026
Same author

Long-term Outcomes in Anomalous Left Coronary Artery From the Pulmonary Artery Syndrome: A Multicenter Half-Century Experience.

CJC pediatric and congenital heart disease·2026
Same author

Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.

Transplantation direct·2026
Same author

Urgent transcatheter tricuspid valve edge-to-edge repair prior to liver and kidney transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

32-Year-Old Woman Presenting With Hemoptysis.

Mayo Clinic proceedings·2025

Related Experiment Video

Updated: Jun 18, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

848

Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Amani Elshaer1, David M H Chascsa2,3, Blanca C Lizaola-Mayo2,3

  • 1Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85054, USA.

Life (Basel, Switzerland)
|July 27, 2024
PubMed
Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing liver condition linked to metabolic issues. Current treatments focus on lifestyle changes and managing other health problems, with new drug therapies under investigation.

Keywords:
bariatric surgerycirrhosisfibrosislifestyle modificationmetabolic-associated steatotic liver diseaseobesitypharmacotherapyweight loss

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.4K

Related Experiment Videos

Last Updated: Jun 18, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

848
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.4K

Area of Science:

  • Hepatology
  • Metabolic Diseases
  • Internal Medicine

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent liver disorder characterized by fat accumulation and associated metabolic risk factors.
  • The increasing incidence of MASLD poses significant risks for severe liver complications and patient morbidity.
  • Effective management strategies are crucial to prevent disease progression and irreversible liver damage.

Purpose of the Study:

  • To review current therapeutic strategies for MASLD.
  • To highlight the multifactorial approach to MASLD treatment, including lifestyle and pharmacological interventions.
  • To discuss emerging pharmacological therapies for enhanced MASLD management.

Main Methods:

  • Literature review of recent research on MASLD treatment.
  • Analysis of current clinical guidelines and therapeutic options.
  • Exploration of ongoing research into novel pharmacological agents.

Main Results:

  • Current MASLD treatment emphasizes weight loss and management of comorbidities.
  • Therapeutic options include lifestyle modifications, pharmacotherapy, and surgical interventions.
  • New pharmacological therapies are under active investigation to improve MASLD treatment outcomes.

Conclusions:

  • MASLD management requires a comprehensive, multifactorial approach.
  • Lifestyle interventions and addressing metabolic risk factors are foundational.
  • Advancements in pharmacological research hold promise for future MASLD treatment enhancement.